Publications by authors named "Hideki Mochida"

Claim this Profile
I
Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists.
Kenneth L Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, Yasuki Niwa, Masakazu Fujio, Hideki Mochida

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure.
Kenneth L Granberg, Shigeki Sakamaki, Niklas Larsson, Fredrik Bergström, Ryuichi Fuchigami, Hideki Mochida

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNAs in urinary nano-extracellular vesicles as potential biomarkers for non-invasive kidney biopsy.
Keisuke Fujitaka, Taku Murakami, Masato Takeuchi, Tetsuhiro Kakimoto, Hideki Mochida

Biomed Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Toshiaki Sakamoto, Yuichi Koga, Masataka Hikota, Kenji Matsuki, Hideki Mochida

Bioorg Med Chem Lett· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs.
Hideki Mochida, Koji Yano, Hirotaka Inoue, Shiyin Yee, Tsunehisa Noto

J Urol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of aging and uninephrectomy on renal changes in Tsukuba hypertensive mice.
Yosuke Inui, Hideki Mochida, Fumiko Yamairi, Miyoko Okada, Junji Ishida

Biomed Rep· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Jun Kotera, Hideki Mochida, Hirotaka Inoue, Tsunehisa Noto, Kotomi Fujishige

J Urol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
Ning Li, Jun-Yan Liu, Valeriy Timofeyev, Hong Qiu, Sung Hee Hwang, Hideki Mochida

J Mol Cell Cardiol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs.
Hideki Mochida, Tsunehisa Noto, Hirotaka Inoue, Koji Yano, Kohei Kikkawa

Eur J Pharmacol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.
Hideki Mochida, Michino Takagi, Hirotaka Inoue, Tsunehisa Noto, Koji Yano

Eur J Pharmacol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Hideki Mochida, Hirotaka Inoue, Michino Takagi, Tsunehisa Noto, Koji Yano

Eur J Pharmacol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis